10-K · March 12, 2026
KORU Medical’s 10-K describes a clear strategy to deepen leadership in the large-volume subcutaneous infusion (SCIg) market via its FREEDOM System while expanding into novel subcutaneous therapies and pharma services.…
Earnings analysis · 10-Q
KRMD earnings analysis
Filed May 6, 2026 · Our reading of the company's report
The latest report
KORU Medical Systems reported strong revenue growth of 22.1% in Q1 2026, reaching $11.8 million driven by domestic and international core businesses as well as significant increases in pharma services and clinical…
Read full summary
KORU Medical Systems reported strong revenue growth of 22.1% in Q1 2026, reaching $11.8 million driven by domestic and international core businesses as well as significant increases in pharma services and clinical trials. Despite a decrease in gross margin to 61.5%, the net loss narrowed to $807,078 compared to a loss of $1.2 million in the prior year, indicating improved operational efficiency.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Gross margin
- 61.5%
What stood out
-
Strong Revenue Growth
Total revenue increased by 22.1% to $11.8 million, up from $9.6 million in Q1 2025.
-
Improved Net Loss
Net loss decreased by 30.8% to $807,078 versus a loss of $1.2 million in the prior year.
-
Growth in Pharma Services
Pharma services and clinical trials revenue surged 166.0%, contributing $740,711 compared to $278,449 last year.
-
Increased Domestic Core Revenue
Domestic core revenue rose 11.7% to $7.7 million, from $6.9 million in Q1 2025.
-
Balance Sheet Liquidity Maintained
Cash on hand was $8.8 million, providing sufficient liquidity for operational needs.
-
Better Operational Cash Flows
Net cash from operating activities improved to $14,663 compared to $(237,467) in Q1 2025.
What to watch
-
Decreasing Gross Margin
Gross margin declined to 61.5% from 62.8% due to rising production costs and tariffs.
-
Potential Economic Headwinds
Management noted risks related to inflation, geopolitical conflicts, and cost recovery that may impact future performance.
-
Dependence on Key Personnel
The risk of losing key personnel remains a concern and could affect strategic plans and operational execution.
Management's outlook
Outlook deferred to earnings press release / call.
Earlier filings 4
10-Q · August 6, 2025
KORU Medical reported Q2 net revenues of $10,194,800, up $1,764,711 (20.9%) versus Q2 2024 and up $559,725 (5.8%) sequentially. Gross margin was 63.5% (6,475,769 gross profit) and operating loss narrowed to $312,655…
10-Q · May 1, 2024
KORU Medical reported Q1 revenue of $8,197,798, up from $7,392,605 a year earlier, with gross profit of $5,103,298 and a gross margin ~62.3%. The company still recorded a GAAP net loss of $1,935,958 (loss per share…
10-Q · May 4, 2023
KORU Medical reported Q1 net sales of $7,392,605, up $1,148,275 (18.4%) versus $6,244,330 a year ago, with gross profit rising to $4,147,035 but gross margin compressing to 56.1%. The company narrowed net loss to…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.